Compare Global X Copper Miners ETF (COPX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Johnson & Johnson — how do they compare? Global X Copper Miners ETF trades at $78.44, while Johnson & Johnson trades at $248.07 (market cap $611.07B). The key difference: Johnson & Johnson pays a 2.11% dividend while Global X Copper Miners ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals.
| COPX | JNJ | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $267.24 |
52-Week Low | $42.75 | $155.17 |
Market Cap | — | $611.07B |
Volume | — | 6,156,228 |
Enterprise Value | — | $644.01B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $74.35, down 2.86% amid bearish technical signals with all 16 moving average indicators signaling sell. The ETF provides exposure to copper mining companies benefiting from AI-driven electrification demand, though key financial ratios remain undisclosed in current data. Recent news highlights copper's structural role in AI infrastructure and energy transition.
Outlook hinges on copper supply-demand dynamics amplified by AI data center expansion, though technical weakness suggests near-term pressure. Risks include commodity price volatility and execution challenges in mining supply chains. Analyst sentiment remains constructive on long-term copper fundamentals despite current bearish technical positioning.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
